On the occasion of the 30th anniversary of the establishment of diplomatic relations between China and Israel, on January 26, under the witness of the Consul General of Israel in Guangzhou, the relevant person in charge of the Guangzhou Development and Reform Commission, Guangzhou Development Zone, Huangpu District Government, Guangdong Pharmaceutical University, and the First Affiliated Hospital of Guangdong Pharmaceutical University, the BIG team and the Guangzhou Sino-Israel Bio-Industry Cooperation Platform signed a strategic cooperation agreement with the First Affiliated Hospital of Guangdong Pharmaceutical University. The new drug clinical trial service platform on Bio Island has thus entered the "fast lane" for implementation.

On the same day, the "Guangzhou BioIsland New Drug Clinical Trial Service Platform" was established jointly by the three parties.

This tripartite cooperation will take the Guangzhou BioIsland New Drug Clinical Trial Service Platform as the carrier, focus on international innovative drugs and medical devices, and integrate the existing medical and enterprise resources in Guangzhou. It aims to enhance the international clinical research and trial level of local medical institutions in Guangzhou and help the city become a national source of new drug innovation, a global hub for new drug clinical trials, and a new highland for the global biopharmaceutical industry.

The ability to innovate in pharmaceuticals and medicine is an important part of a country's and a city's comprehensive strength. The system serving international new drug clinical trials is both Guangzhou's potential and a new opportunity for urban development. Focusing on this industrial issue, under the guidance of the government, the High-tech Group, the Bio-Island Company, and BIG&GIBF team have actively carried out domestic and international research and local interviews with top-tier hospitals and industry enterprises (including Fortune 500 companies, multinational corporations, and listed companies) since 2018, continuously exploring and verifying the operational path for building the Guangzhou BioIsland New Drug Clinical Trial Service Platform.

The Guangzhou BioIsland New Drug Clinical Trial Service Platform is committed to becoming an "empowerer" for improving the clinical trial system, a "transformer" for promoting clinical achievements, and an "introducer" for bringing top international innovative drugs to Guangzhou. 

Since the launch of China-Israel cooperation in Guangzhou in 2013, the two sides have adopted a systematic, pragmatic, and innovative model of "one investment fund, one incubation base, and one China-Israel joint team," achieving a cluster of pioneering innovative technologies in a small area in Guangzhou. This model has not only been affirmed by the Israeli authorities but has also attracted the recognition of local governments in Shanghai, Beijing, Chongqing, Chengdu, Shenzhen, Changzhou, Suzhou, Nanjing, and Fujian, who have repeatedly invited the Guangzhou China-Israel team to cooperate.The Guangzhou BioIsland New Drug Clinical Trial Service Platform is also a new achievement jointly created by China-Israel cooperation in Guangzhou, following BIG & GIBF.